Faster IgG4 Depletion Kinetics Observed for Anti-Desmoglein 3 Autoantibodies Following Rituximab Treatment in Patients with Pemphigus Vulgaris

Authors

  • Katharina Boch Department of Dermatology, University of Lübeck, Lübeck, Germany
  • Ewan A. Langan Department of Dermatology, University of Lübeck, Lübeck, Germany; Manchester Sciences, University of Manchester, Manchester, United Kingdom
  • Nina van Beek Department of Dermatology, University of Lübeck, Lübeck, Germany; Lübeck Institute of Experimental Dermatology, University of Lübeck, Lübeck, Germany
  • Khalaf Kridin Lübeck Institute of Experimental Dermatology, University of Lübeck, Lübeck, Germany; Azrieli Faculty of Medicine, Bar-Ilan University, Safed, Israel
  • Enno Schmidt Department of Dermatology, University of Lübeck, Lübeck, Germany; Lübeck Institute of Experimental Dermatology, University of Lübeck, Lübeck, Germany
  • Detlef Zillikens Department of Dermatology, University of Lübeck, Lübeck, Germany
  • Ralf J. Ludwig Lübeck Institute of Experimental Dermatology, University of Lübeck, Lübeck, Germany
  • Christoph M. Hammers Department of Dermatology, University of Lübeck, Lübeck, Germany; Lübeck Institute of Experimental Dermatology, University of Lübeck, Lübeck, Germany
  • Katja Bieber Lübeck Institute of Experimental Dermatology, University of Lübeck, Lübeck, Germany

DOI:

https://doi.org/10.2340/actadv.v102.4490

Keywords:

Pemphigus, IgG4, Rituximab, autoantibody

Abstract

Abstract is missing (Short communication)

Downloads

Download data is not yet available.

References

Schmidt E, Kasperkiewicz M, Joly P. Pemphigus. Lancet 2019; 394: 882-894.

https://doi.org/10.1016/S0140-6736(19)31778-7 DOI: https://doi.org/10.1016/S0140-6736(19)31778-7

Futei Y, Amagai M, Ishii K, Kuroda-Kinoshita K, Ohya K, Nishikawa T. Predominant IgG4 subclass in autoantibodies of pemphigus vulgaris and foliaceus. J Dermatol Sci 2001; 26: 55-61.

https://doi.org/10.1016/S0923-1811(00)00158-4 DOI: https://doi.org/10.1016/S0923-1811(00)00158-4

Funakoshi T, Lunardon L, Ellebrecht CT, Nagler AR, O'Leary CE, Payne AS. Br J Dermatol 2012; 167: 1245-1253.

https://doi.org/10.1111/j.1365-2133.2012.11144.x DOI: https://doi.org/10.1111/j.1365-2133.2012.11144.x

Kricheli D, David M, Frusic-Zlotkin M, Goldsmith D, Rabinov M, Sulkes J, et al. The distribution of pemphigus vulgaris-IgG subclasses and their reactivity with desmoglein 3 and 1 in pemphigus patients and their first-degree relatives. Br J Dermatol 2000; 143: 337-342.

https://doi.org/10.1046/j.1365-2133.2000.03659.x DOI: https://doi.org/10.1046/j.1365-2133.2000.03659.x

Joly P, Horvath B, Patsatsi Α, Uzun S, Bech R, Beissert S, et al. Updated S2K guidelines on the management of pemphigus vulgaris and foliaceus initiated by the european academy of dermatology and venereology (EADV). J Eur Acad Dermatol Venereol 2020; 34: 1900-1913.

https://doi.org/10.1111/jdv.16752 DOI: https://doi.org/10.1111/jdv.16752

Golinski ML, Lemieux A, Maho-Vaillant M, Barray M, Drouot L, Schapman D, et al. The diversity of serum anti-DSG3 IgG subclasses has a major impact on pemphigus activity and is predictive of relapses after treatment with rituximab. Front Immunol 2022; 13: 849790.

https://doi.org/10.3389/fimmu.2022.849790 DOI: https://doi.org/10.3389/fimmu.2022.849790

Mignard C, Maho-Vaillant M, Golinski ML, Balayé P, Prost-Squarcioni C, Houivet E, et al. Factors associated with short-term relapse in patients with pemphigus who receive rituximab as first-line therapy: a post hoc analysis of a randomized clinical trial. JAMA Dermatol 2020; 156: 545-552.

https://doi.org/10.1001/jamadermatol.2020.0290 DOI: https://doi.org/10.1001/jamadermatol.2020.0290

Boch K, Langan EA, Schmidt E, Zillikens D, Ludwig RJ, Bieber K, et al. Sustained CD19+CD27+ memory B cell depletion after rituximab treatment in patients with pemphigus vulgaris. Acta Derm Venereol 2022; 102: adv00679.

https://doi.org/10.2340/actadv.v102.907 DOI: https://doi.org/10.2340/actadv.v102.907

Koneczny I. Update on IgG4-mediated autoimmune diseases: new insights and new family members. Autoimmun Rev 2020; 19: 102646.

https://doi.org/10.1016/j.autrev.2020.102646 DOI: https://doi.org/10.1016/j.autrev.2020.102646

Dalakas MC. Autoimmune neurological disorders with IgG4 antibodies: a distinct disease spectrum with unique IgG4 functions responding to anti-B Cell therapies. Neurotherapeutics 2022; 19: 741-752.

https://doi.org/10.1007/s13311-022-01210-1 DOI: https://doi.org/10.1007/s13311-022-01210-1

Goebeler M, Bata-Csörgő Z, De Simone C, Didona B, Remenyik E, Reznichenko N, et al. Treatment of pemphigus vulgaris and foliaceus with efgartigimod, a neonatal Fc receptor inhibitor: a phase II multicentre, open-label feasibility trial. Br J Dermatol 2022; 186: 429-439.

https://doi.org/10.1111/bjd.20782 DOI: https://doi.org/10.1111/bjd.20782

Tavakolpour S, Mahmoudi H, Mirzazadeh A, Balighi K, Darabi-Monadi S, Hatami S, et al. Pathogenic and protective roles of cytokines in pemphigus: a systematic review. Cytokine 2020; 129: 155026.

https://doi.org/10.1016/j.cyto.2020.155026 DOI: https://doi.org/10.1016/j.cyto.2020.155026

Published

2022-12-13

How to Cite

Boch, K., Langan, E. A., van Beek, N., Kridin, K., Schmidt, E., Zillikens, D., Ludwig, R. J., Hammers, C. M., & Bieber, K. (2022). Faster IgG4 Depletion Kinetics Observed for Anti-Desmoglein 3 Autoantibodies Following Rituximab Treatment in Patients with Pemphigus Vulgaris. Acta Dermato-Venereologica, 102, adv00835. https://doi.org/10.2340/actadv.v102.4490

Issue

Section

Short Communication

Categories